Development of UV Spectroscopic Method for Nefopam and Escitalopram as INN Drugs in Tablet Dosage Form
AbstractNefopam and Escitalopram are INN drugs and as such it has not been yet included in the BP or USP. The objective of this work is to develop a simple, sensitive, accurate, precise and reproducible UVSpectrophotometric method for quantitative estimation of Nefopam and Escitalopram in tablet dosage forms. Various solvents were used to find out the medium for maximum solubility of each drug. The χmax of Nefopam and Escitalopram was 266nm and 284nm in water respectively. Both drugs obey Beer- Lambert’s law in the range of 50-400μg/ml for Nefopam and 25-200μg/ml for Escitalopram. The correlation coefficients of std. curves were 0.998 and 0.995. The values of SD were 0.131 and 0.081 respectively. %RSD (Relative standard deviation) of interday absorbance of Nefopam was 0.766 and Escitalopram was 0.854. The LOD (Limit of Detection) were 0.393 and 0.243 and LOQ (Limit of Quantification) were 1.310 and 0.810 respectively. The percent potencies were 92.16 and 102.06 for Nefopam and Escitalopram. The potency of these tablets complied with their claimed quantity (±10%). So, based on these data, it may be concluded that these proposed method are simple, sensitive, precise, reproducible and accurate for the analysis of these drugs in tablet dosage form.
Key Words: INN drugs; correlation coefficients; LOD; LOQ; Nefopam; Escitalopram.
S. J. Pharm. Sci. 3(1): 4-10
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.